Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA cough/cold monograph

This article was originally published in The Tan Sheet

Executive Summary

Sept. 11 "feedback" meeting set for Vaporizer in a Bottle marketer Lil' Drug Store, FDA says. The meeting will take place at 2 p.m. at 9201 Corporate Blvd., Rockville, Md. Firm is seeking guidance on proposed clinical trial methodologies on the combination antitussive product to gain inclusion in the OTC Drug Cough, Cold, Allergy, Bronchodilator & Antiasthmatic Combination Drug Product Final Mongraph as an antitussive (1"The Tan Sheet" Aug. 4, 2003, In Brief)...

You may also be interested in...



Cough/cold combinations

Lil' Drug Store asks for agency feedback meeting on "methodology and appropriateness" of proposed clinical or equivalence studies on its Vaporizer in a Bottle product before commencing trials to support inclusion in the OTC cough/cold combination final monograph. Firm's June 19 letter requests input on in vitro and clinical study appropriateness and methodology; mobility/proximity; combination versus single ingredient formulation; and "statistical significance level required to demonstrate effectiveness." Final monograph was published December 2002 (1"The Tan Sheet" Dec. 23, 2002, p. 3)...

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel